Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Baxter
Moodys
Colorcon
Farmers Insurance
Mallinckrodt
McKesson
Fish and Richardson
AstraZeneca
Citi

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,621,891

« Back to Dashboard

Which drugs does patent 7,621,891 protect, and when does it expire?


Patent 7,621,891 protects TWINJECT 0.15 and TWINJECT 0.3 and is included in one NDA.

This patent has forty-three patent family members in fifteen countries.

Summary for Patent: 7,621,891

Title:Method and apparatus for delivering epinephrine
Abstract:A method of administering liquid medicine such as epinephrine to a patient includes administering a first dose followed by administering an optional second dose is described herein. Also described herein are devices useful for carrying out the methods described and kits containing these devices.
Inventor(s): Wyrick; Ronald (Spokane, WA)
Assignee: Washington Biotech Corporation (Spokane, WA)
Application Number:11/276,460
Patent Claim Types:
see list of patent claims
Formulation; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Impax Labs Inc
TWINJECT 0.15
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-002May 28, 2004DISCNNoNo► Subscribe► SubscribeY
Impax Labs Inc
TWINJECT 0.3
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-001May 30, 2003DISCNNoNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,621,891

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,187,224Methods performed by medicine injection apparatuses► Subscribe
7,297,136Medicine injection devices and methods► Subscribe
7,927,303Medicine injection devices and methods► Subscribe
7,931,618Apparatuses and methods for injecting medicines to a desired depth► Subscribe
7,905,352Kits containing medicine injection devices and containers► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,621,891

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2005314174► Subscribe
Australia2005314401► Subscribe
BrazilPI0518415► Subscribe
BrazilPI0518460► Subscribe
Canada2585707► Subscribe
Canada2589899► Subscribe
Canada2826821► Subscribe
China101072595► Subscribe
China101072604► Subscribe
China101850143► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Colorcon
Covington
Novartis
Teva
UBS
Cerilliant
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot